8-K: AngioDynamics Appoints New CEO, Transition Plan in Place

AngioDynamics announced the appointment of Eric Honroth as its new President and CEO, effective November 2, 2026, succeeding James C. Clemmer who will transition to a consulting role.

Summary

• AngioDynamics has appointed Eric Honroth as its new President and Chief Executive Officer, effective November 2, 2026.
• Eric Honroth will also join the Board of Directors.
• James C. Clemmer will retire as CEO on November 2, 2026, and will serve as a consultant to the company for one year to ensure a smooth transition.
• Mr. Honroth brings over 20 years of experience in the medical device and life sciences industries, with a background in cardiovascular, endovascular, urology, and oncology markets.
• His prior roles include leadership positions at Getinge AB, Abbott Vascular, Becton Dickinson, CareFusion, and Boston Scientific.
• Mr. Honroth's employment agreement includes a base salary of $735,000, eligibility for an annual bonus, and significant long-term incentive awards.
• James C. Clemmer will receive a monthly consulting fee of $30,000 for his services.
• The company has also entered into retention agreements with its executive leadership team to incentivize continued employment through the CEO transition.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, marking a significant leadership transition with a well-qualified successor and clear continuity plans.

Positives

• Appointment of Eric Honroth, a seasoned executive with extensive experience in relevant medical technology markets, as the new CEO.
• Clear succession plan with James C. Clemmer transitioning to a consulting role to ensure continuity.
• Mr. Honroth's track record of accelerating growth and improving profitability at previous companies.
• AngioDynamics' stated momentum, including a high-growth Med Tech segment and a strong balance sheet with no outstanding debt.
• Retention agreements designed to incentivize key executive leadership through the transition period.

Negatives

• The departure of a long-serving CEO (James C. Clemmer) who has guided the company through a significant transformation.
• The inherent uncertainty and potential disruption associated with any major leadership change, despite transition plans.

Risks

• Potential challenges in integrating a new CEO's leadership style and strategic vision with the existing company culture and operations.
• The risk that forward-looking statements regarding growth, margin expansion, and shareholder value may not be realized.
• Factors that may affect actual results, as detailed in the 'Safe Harbor' statement, including market conditions, regulatory actions, and competitive pressures.

Future Outlook

The company anticipates that the new CEO, Eric Honroth, will build on the company's existing momentum, advance its transformation, and drive sustainable revenue growth, margin expansion, and long-term shareholder value. The press release highlights a high-growth Med Tech segment and a strong balance sheet as foundations for future success.

Management Comments

• "AngioDynamics enters this transition with real momentum, including a high-growth Med Tech segment, a strong balance sheet with no outstanding debt, and an operational transformation that is delivering," said Howard Donnelly, AngioDynamics Board Chair.
• "Eric has done what this moment requires. He has built businesses, driven profitable growth, and managed global operations with responsibility for both revenue and cost structure. He also builds teams and leads with a genuine commitment to patients, and the Board is confident he is the right leader to deliver long-term value during our next chapter," continued Mr. Donnelly.
• "On behalf of the Board, I want to thank Jim for his exceptional leadership over the past decade. Under his guidance, AngioDynamics underwent a successful transformation that sharpened our focus and built a solid foundation for sustainable growth and profitability. Jim's dedication to our team, patients, customers, and shareholders has left a lasting mark on the Company, and we are deeply grateful for his many contributions. We look forward to his continued contributions as a trusted senior advisor," added Mr. Donnelly.
• "I am honored to lead AngioDynamics at such an important moment for the Company and grateful for the confidence the Board and Jim have placed in me," said Mr. Honroth. "The Company has a differentiated technology portfolio, multiple growth drivers, and an exceptionally talented team. I look forward to working with employees and customers to build on this foundation and accelerate progress where we see the greatest opportunities to improve patient care and create shareholder value."
• "It has been the privilege of my career to lead AngioDynamics these past ten years," said Mr. Clemmer. "Together, we sharpened the Company's focus, expanded operating capabilities, and positioned the business for its next phase of growth. I am confident Eric's experience and leadership make him the right person to carry that work forward, and I look forward to supporting a smooth transition."

Industry Context

StockSavvy.ai notes that the appointment of Eric Honroth, with his extensive background in cardiovascular, endovascular, and oncology markets at companies like Abbott Vascular and Boston Scientific, aligns with AngioDynamics' focus on restoring blood flow and expanding cancer treatment options. This type of leadership transition is common in the dynamic medical technology sector, where experienced executives are sought to drive innovation and market penetration.

Management Changes

Stakeholder Impact

• Shareholders: The appointment of an experienced CEO is generally viewed positively, aiming to drive long-term value. The retention of key executives aims to ensure stability during the transition.
• Employees: The retention agreements aim to provide incentives for continued employment and commitment during the leadership change. The new CEO's focus on building teams is also a positive indicator.
• Customers: Continuity in leadership and a focus on improving patient care and driving growth are expected to benefit customers.
• Creditors: The company's strong balance sheet and focus on revenue growth and margin expansion are positive for creditors.

Next Steps

• Eric Honroth to commence service as President and Chief Executive Officer on November 2, 2026.
• James C. Clemmer to provide consulting services to the Company until the first anniversary of the Effective Date (November 2, 2027).
• Executive leadership team to remain employed through the transition period to receive retention incentives.
• Continued focus on advancing the company's transformation, driving revenue growth, and expanding margins.

Key Dates

Recommendation

The filing announces a planned leadership transition with a well-qualified successor and a clear plan for continuity. While this is a positive step, it does not provide new financial performance data or strategic shifts that would warrant a change in investment recommendation. The company's future performance will depend on the new CEO's execution. Therefore, a 'hold' recommendation is appropriate pending further operational and financial updates under the new leadership.

Keywords

CEO Appointment, Leadership Transition, Medical Technology, Executive Employment, Corporate Governance, Board of Directors, Consulting Agreement, Retention Incentive